Literature DB >> 25263222

A mechanistic theory to explain the efficacy of antiretroviral therapy.

Sarah B Laskey1, Robert F Siliciano2.   

Abstract

In the early years of the AIDS epidemic, a diagnosis of HIV-1 infection was equivalent to a death sentence. The development of combination antiretroviral therapy (cART) in the 1990s to combat HIV-1 infection was one of the most impressive achievements of medical science. Today, patients who are treated early with cART can expect a near-normal lifespan. In this Opinion article, we propose a fundamental theory to explain the mechanistic basis of cART and why it works so well, including a model to assess and predict the efficacy of antiretroviral drugs alone or in combination.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25263222     DOI: 10.1038/nrmicro3351

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  81 in total

Review 1.  The choreography of HIV-1 proteolytic processing and virion assembly.

Authors:  Sook-Kyung Lee; Marc Potempa; Ronald Swanstrom
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

2.  Update of the drug resistance mutations in HIV-1: March 2013.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Gunthard; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2013 Feb-Mar

3.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

5.  Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.

Authors:  Jean-Luc Meynard; Vincent Bouteloup; Roland Landman; Philippe Bonnard; Vincent Baillat; André Cabie; Sami Kolta; Jacques Izopet; Anne-Marie Taburet; Patrick Mercie; Geneviève Chene; Pierre-Marie Girard
Journal:  J Antimicrob Chemother       Date:  2010-09-15       Impact factor: 5.790

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

Review 8.  A novel method for determining the inhibitory potential of anti-HIV drugs.

Authors:  Lin Shen; S Alireza Rabi; Robert F Siliciano
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

9.  Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.

Authors:  Ahmad R Sedaghat; Janet D Siliciano; Timothy P Brennan; Claus O Wilke; Robert F Siliciano
Journal:  PLoS Pathog       Date:  2007-08-31       Impact factor: 6.823

10.  Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells.

Authors:  Boghuma Kabisen Titanji; Marlen Aasa-Chapman; Deenan Pillay; Clare Jolly
Journal:  Retrovirology       Date:  2013-12-24       Impact factor: 4.602

View more
  30 in total

1.  Trehalose Inhibits Human Immunodeficiency Virus Type 1 Infection in Primary Human Macrophages and CD4+ T Lymphocytes through Two Distinct Mechanisms.

Authors:  Pratima Rawat; Simson Hon; Carmen Teodorof-Diedrich; Stephen A Spector
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Kinetic Differences and Synergistic Antiviral Effects Between Type I and Type III Interferon Signaling Indicate Pathway Independence.

Authors:  Emily A Voigt; John Yin
Journal:  J Interferon Cytokine Res       Date:  2015-05-04       Impact factor: 2.607

Review 3.  Predictive approaches for drug combination discovery in cancer.

Authors:  Seyed Ali Madani Tonekaboni; Laleh Soltan Ghoraie; Venkata Satya Kumar Manem; Benjamin Haibe-Kains
Journal:  Brief Bioinform       Date:  2018-03-01       Impact factor: 11.622

4.  Capacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks.

Authors:  Natalia Freitas; Tetyana Lukash; Megan Dudek; Sam Litwin; Stephan Menne; Severin O Gudima
Journal:  Virus Res       Date:  2015-05-12       Impact factor: 3.303

5.  Quantitative evaluation of the antiretroviral efficacy of dolutegravir.

Authors:  Sarah B Laskey; Robert F Siliciano
Journal:  JCI Insight       Date:  2016-11-17

Review 6.  Immune escape mechanisms as a guide for cancer immunotherapy.

Authors:  Gregory L Beatty; Whitney L Gladney
Journal:  Clin Cancer Res       Date:  2014-12-12       Impact factor: 12.531

Review 7.  HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy.

Authors:  Luis M Agosto; Pradeep D Uchil; Walther Mothes
Journal:  Trends Microbiol       Date:  2015-03-09       Impact factor: 17.079

8.  Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics.

Authors:  Weiming Yang; Brooks Jackson; Hui Zhang
Journal:  Proteomics       Date:  2016-06-08       Impact factor: 3.984

9.  Subclinical Genital Herpes Shedding in HIV/Herpes Simplex Virus 2-Coinfected Women during Antiretroviral Therapy Is Associated with an Increase in HIV Tissue Reservoirs and Potentially Promotes HIV Evolution.

Authors:  Tajanna Stinn; Steve Kuntz; Dana Varon; Meei-Li Huang; Stacy Selke; Samuel Njikan; Emily S Ford; Joan Dragavon; Robert W Coombs; Christine Johnston; Marta E Bull
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

Review 10.  Targeting the Latent Reservoir for HIV-1.

Authors:  Srona Sengupta; Robert F Siliciano
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.